Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Bioventus (BVS) Short-term Investments (2021 - 2022)

Bioventus filings provide 2 years of Short-term Investments readings, the most recent being $23000.0 for Q4 2022.

On a quarterly basis, Short-term Investments fell 99.56% to $23000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $23000.0, a 99.56% decrease, with the full-year FY2022 number at $23000.0, down 99.56% from a year prior.
Short-term Investments hit $23000.0 in Q4 2022 for Bioventus, roughly flat from $23000.0 in the prior quarter.
In the past five years, Short-term Investments ranged from a high of $5.3 million in Q4 2021 to a low of $23000.0 in Q4 2022.